Advertisement Novo Nordisk Pharmatech Enters Distribution Agreement with HELM de México - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More

Novo Nordisk Pharmatech A/S

Supplier of Quaternary Ammonium Compounds and Recombinant Insulin Human AF

Novo Nordisk Pharmatech Enters Distribution Agreement with HELM de México

Novo Nordisk Pharmatech A/S has entered an agreement with HELM de México to distribute pharmaceutical grade quaternary ammonium compounds (Quats) to the healthcare industry in Mexico. HELM de México, S.A. is founded with German capital in 1966 and is a family-owned company limited by shares under German law.

Boy Ehlers, Managing Director of HELM de Mexico, commented on this new collaboration: “We are very excited to announce the new distribution agreement between HELM de México and Novo Nordisk Pharmatech. We believe it is a mutually beneficial agreement. On the one hand, Novo Nordisk Pharmatech will gain access to HELM ´s extensive network of customers in the pharmaceutical/cosmetics industry along with the distribution infrastructure HELM has built in the 55 years we have been present in the Mexican market. On the other hand, we at HELM de México are extremely proud to add a tremendously prestigious brand like Novo Nordisk Pharmatech to our portfolio of products and solutions we offer to our customers. This will help us further increase the relevance of our range of products with our clients. We are looking forward to growing this business together with Novo Nordisk Pharmatech in Mexico.”

Novo Nordisk Pharmatech A/S is a global and leading manufacturer of pharmaceutical ingredients for the pharmaceutical and biopharmaceutical industries. The company specializes in Quats (Benzalkonium Chloride, Cetyl Trimethyl Ammonium Bromide (CTAB) and Cetrimide) used as active pharmaceutical ingredients (APIs) and excipients in the highest available quality standard – and Recombinant Insulin for use in cell culture media to enhance cell growth, viability, and productivity.

The products comply with the latest pharmacopoeial standards and are extensively supported by CEPs, DMFs and a comprehensive regulatory and quality assurance document package. In addition, the manufacturing site in Køge (Denmark) is audited by the Danish Medicines Agency and US FDA.
“We have been operating on the American continent for a while now, mainly in North America and Brazil. Hence, we are announcing our partnership with HELM de México for the Mexican territory with great pleasure. HELM is an excellent partner who can meet the highest demands in compliance, quality and customer experience. We are looking forward to a long and fruitful relationship.” says Timur Özbay, Head of Sales at Novo Nordisk Pharmatech A/S.